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KESAN METILASI DNA KEPULAUAN CpG TERHADAP AKTIVITI 




Kolina kinase (CK) adalah enzim sitosolik yang merupakan pemangkin yang 
terlibat dalam fosforilasi kolina kepada penghasilan fosfokolina (PCho) dalam proses 
biosintesis fosfatidilkolina (PC), komponen utama dalam fosfolipid membran. Di sebalik 
kepentingan CK dalam biosintesis PC, pertumbuhan sel dan karsinogenesis, maklumat 
berkaitan pengawalaturan transkripsi gen ckα masih terhad. Kewujudan kepulauan CpG 
di bahagian promoter gen ckα mencadangkan penglibatan metilasi DNA dalam 
pengawalaturan transkripsi gen ckα. Oleh itu, kajian ini bertujuan untuk mengkaji kesan 
metilasi DNA kepulauan CpG terhadap aktiviti promoter gen ckα. Promoter gen ckα 
bersaiz 2009 bp telah diklonkan ke dalam vektor pelapor, firefly luciferase (pGL4.10) 
untuk menghasilkan plasmid rekombinan, pGL4.10-ckα (-2000/+9). Kemudian, satu siri 
mutasi penghapusan kepulauan CpG telah dihasilkan dengan kaedah mutagenesis 
berpandu tapak PCR, dan diklon ke dalam vektor pGL4.10 untuk dikaji dalam sel 
adenokarsinoma payudara manusia, MCF-7. Status metilasi selepas rawatan dengan 
menggunakan agen pengurangan metilasi, 5-azasitidina dan agen penambahan metilasi, 
budesonida menunjukkan peranan metilasi DNA di bahagian promoter gen ckα yang 
lebih ketara dalam sel kanser MCF-7 berbanding sel normal MCF10A. Sebanyak empat 
kepulauan CpG telah dikenalpasti di dalam kawasan promoter ini menggunakan perisian 
MethPrimer dan EMBOSS CpGPlot. Penyingkiran pada kawasan -225 ke -56 bp dalam 
kepulauan CpG keempat menunjukkan peningkatan aktiviti promoter berbanding dengan 
xxi 
 
promoter berkepanjangan penuh. Ini menunjukkan adanya unsur pengawalseliaan 
negatif yang penting yang mungkin dimodulasikan oleh metilasi DNA. Analisis in vitro 
menunjukkan metilasi promoter berkepanjangan penuh menghasilkan aktiviti yang lebih 
rendah jika dibandingkan dengan metilasi promoter yang terhapus kepulauan CpG 
keempat. Ini menggambarkan bahawa kepulauan CpG ini mungkin mengandungi tapak 
pengikatan untuk faktor transkripsi penghalang. Mutasi tapak pengikatan MZF1 
menunjukkan peningkatan yang signifikan dalam aktiviti promoter ckα berbanding 
dengan promoter ckα berkepanjangan penuh sekaligus menunjukkan sifatfungsi 
perencatan elemen jujukan ini. Analisis EMSA menunjukkan terdapat pengikatan faktor 
transkripsi pada bahagian tapak perlekatan MZF1, dan metilasi sitosina pada bahagian 
ini menunjukkan peningkatan terhadap pengikatan faktor MZF1 jangkaan ini di 
bahagian -181 sehingga -175 pada promoter ckα. Tambahan lagi, mutasi pada tapak 
perlekatan MZF1 menghapuskan pembentukan kompleks protein-DNA. Ini 
menunjukkan bahawa metilasi DNA mengurangkan aktiviti promoter ckα dengan cara 
mempromosikan pengikatan faktor transkripsi MZF1 di kepulauan CpG keempat pada 
bahagian -225/-56. Sebagai kesimpulan, kajian ini memberi perspektif mengenai 
penglibatan kepulauan CpG dan metilasi DNA dalam pengawalaturan transkripsi gen 









EFFECTS OF CpG ISLANDS DNA METHYLATION ON THE HUMAN 




Choline kinase (CK) is a cytosolic enzyme catalyzing the phosphorylation of 
choline to phosphocholine (PCho) in the biosynthesis of phosphatidylcholine (PC), a 
major component of membrane phospholipid. Despite the importance of CK in PC 
biosynthesis, cell growth and carcinogenesis, little is known about the transcriptional 
regulation of ckα gene. The presence of CpG islands on the promoter region of ckα gene 
suggests the involvement of DNA methylation in its transcriptional control. Therefore, 
this study aimed to investigate the effects of CpG islands DNA methylation on ckα gene 
promoter activity. A 2009 bp promoter region of the human ckα gene was cloned into a 
firefly luciferase reporter vector (pGL4.10) to create a recombinant plasmid, pGL4.10-
ckα (-2000/+9). Then, a series of CpG island deletion mutants were constructed using 
PCR site-directed mutagenesis method and cloned into pGL4.10 vector and studied in 
human breast adenocarcinoma, MCF-7 cells. The methylation status after treatment with 
a demethylating agent, 5-azacytidine and re-methylating agent, budesonide showed a 
prominent role of DNA methylation of ckα gene promoter in MCF-7 cancer cells 
compared to the corresponding normal cells MCF10A. A total of four CpG islands were 
identified within the promoter region by using MethPrimer and EMBOSS CpGPlot 
software. Deletion of the region between -225 to -56 bp in the fourth CpG island showed 
an increased promoter activity as compared to the full-length promoter indicating the 
presence of important negative regulatory elements which could be modulated by DNA 
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methylation. An in vitro methylation analysis showed the methylated full-length 
promoter activity was significantly lower than the methylated fourth CpG island deletion 
suggesting that this CpG island contains elements for the binding of suppressor 
transcription factors. Mutation of MZF1 binding site in the fourth CpG island caused a 
significant increase in the ckα promoter activity, suggesting a repressive role of this 
sequence element. EMSA analysis showed that there is a binding of transcription factor 
to the MZF1 binding site, and the cytosine methylation at this site showed an increase of 
the binding of this putative MZF1 transcription factor at -181 to -175 ckα promoter 
region. Furthermore, mutation of MZF1 binding site abolished the protein-DNA 
formation complex. These results suggest that DNA methylation decreased the ckα 
promoter activity by promoting the binding of MZF1 transcription factor to the fourth 
CpG island located at -225 to -56 region. In conclusion, this study provides a perspective 















Choline kinases (CK) (EC 2.7.1.32) are cytosolic enzymes catalyzing the 
phosphorylation of choline to phosphocholine (PCho) in the biosynthesis of the 
phosphatidylcholine (PC) (Wu et al., 2008). PC is the primary phospholipid of 
eukaryotic cellular membranes and has crucial roles in the structure and function of 
those membranes (Gibellini and Smith, 2010). Human CK is encoded by two separate 
genes named ckα and ckβ. ckβ codes for a single protein (CKβ) while ckα undergoes 
alternative splicing to produce CKα1 and CKα2 isoenzymes (Gallego-Ortega et al., 
2011). Increased activities of CK and PCho have been implicated in human 
carcinogenesis where CK overexpression increases the invasiveness and drug resistance 
of breast cancer cells (Shah et al., 2010). Many researchers have focused on the 
abnormal expression of ckα in various human cancers such as colorectal, lung, and 
prostate adenocarcinomas (Nakagami et al., 1999; Ramirez de Molina, 2002; Rizzo et 
al., 2021) and the potential of ckα inhibition as anticancer therapy. Yet, the regulation of 
CK gene expression at the transcriptional level, particularly by epigenetic mechanism, 
has never been explored. 
 
Epigenetics is defined as a heritable process that alters gene activity without changing 
the DNA sequence (Weinhold, 2006). Epigenetic processes are natural and vital to many 
organism functions, and abnormal epigenetic changes often lead to dysregulation of 
developmental activities (Hon et al., 2012). DNA methylation is the most well-studied 
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epigenetic mechanism that involved in diverse cellular function, including silencing of 
transposable elements, inactivation of viral sequences, maintenance of chromosomal 
integrity, X-chromosome inactivation, and transcriptional suppression of a large number 
of genes (Lister et al., 2009; Olkhov-Mitsel and Bapat, 2012). In somatic cells, DNA 
methylation occurs at cytosine in any context of the genome but predominantly in a 
cytosine-phosphate-guanine (CpG) dinucleotide context (Jin et al., 2011). Methylated 
CpGs augment transcription repression by a number of processes, including the direct 
blockage of transcription initiation complexes from binding to DNA promoter regions 
and recruitment of transcriptional repressor complexes, including methyl CpG binding 
proteins (MBPs) that bind at methylated DNA sequence (Sasai et al., 2010). Aberrant 
methylation levels have been postulated to inactivate tumor suppressors and activate 
oncogenes, which lead to carcinogenesis (Gal-Yam et al., 2008). 
 
In mammals, methylation occurs predominantly at the CpG dinucleotides, which are 
extremely depleted in the genome except at a short stretch genomic region termed as 
CpG islands, which are usually located at gene promoters (Deaton and Bird, 2011). 
Roughly about 50% of mammalian gene promoters are associated with one or more CpG 
islands, making this the most common promoter type in the vertebrate genome 
(Ioshikhes and Zhang, 2000). While the CpG dinucleotides in the genome are heavily 
methylated, the CpG dinucleotides in these islands remain unmethylated. Inactivation of 
numerous numbers of genes has been associated with the increased CpG island 
methylation in tumors such as hMTLH1, p16, MGMT, BRCA1, and CCDN2 (Lian et al., 
2012). Hence, methylation of CpG islands is an important mechanism for gene 
inactivation in the prevention of tumor growth and development.  
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1.2 Rationale of the study 
Despite the importance of CK in PC biosynthesis, embryogenesis, muscular dystrophy 
and tumorigenesis, literature describing transcriptional regulation of ckα gene is still 
lacking. Higher level of ckα is a common feature in many types of cancer. Over the 
years, enormous efforts have been focused on investigating the expression of CK in 
different cancer cells which led to the use of CK inhibitors as potential anticancer agents 
(Trousil et al., 2016; Zimmerman and Ibrahim, 2017; Khalifa et al., 2020). 
Unfortunately, less attention has been given to the intracellular regulation of choline 
kinase gene expression including by epigenetic mechanism. DNA methylation of CpG 
islands especially on the promoter of a gene is one of the mechanisms that regulate the 
gene expression at transcriptional level. 
 
Analysis of 5’ flanking region of ckα gene showed that it possesses characteristics of a 
housekeeping gene which are: absence of TATA box in close proximity to the 
transcription start site and containing several proximal CCAAT boxes as well as Sp1 
binding sites (Aoyama et al., 2004). The TATA-less and high GC-rich sequence 
promoters are typically characterized as CpG island promoter, generally associated with 
DNA methylation. The presence of numerous Sp1 binding sites indicates that the ckα 
promoter contains high GC contents which led to the assumptions that transcriptional 
regulation of ckα gene might be controlled through DNA methylation at the promoter 
region. Based on the presence of several CpG islands on the promoter region, we 
hypothesize that the levels of DNA methylation in the ckα promoter could be affected by 
epigenetic drugs such as 5-azacytidine, a demethylating agent and budesonide, a 
methylating agent. MCF-7 cell line was used for the analysis of DNA methylation as it 
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showed the highest promoter activity compared to the other cell lines and could activate 
the transcription of firefly luciferase for promoter study (Kuan et al., 2014).  
 
DNA methylation is suggested to modulate the binding of transcription factors to DNA 
(Héberlé and Bardet, 2019). Our previous studies have identified important transcription 
factor binding sites in the promoter region of ckα gene. Hence, this study aimed to 
investigate the correlation between DNA methylation of CpG island and transcription 
factor binding based on the overlaps between methylation sites and transcription factor 
binding motifs. From this study, the involvement of CpG island and DNA methylation in 
the transcriptional control of ckα gene would be elucidated.  
 
1.3 Objectives of the study 
1.3.1 General objective 
To study the effect of DNA methylation on ckα CpG islands promoter activity.  
 
1.3.2 Specific objectives 
1. To identify putative CpG islands of human ckα promoter by in silico analysis. 
2. To determine the level of methylation on the methylation-prone CpG island of 
ckα promoter. 
3. To identify important CpG islands that regulate the activities of ckα promoter by 
site-directed mutagenesis. 
4. To investigate the effects of 5-azacytidine and budesonide on ckα promoter 
activity in MCF-7 cell lines. 
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5. To confirm the binding of transcription factors on methylation-prone CpG island 











































Back in 1915, membranes isolated from red blood cells were found to be composed of 
lipids and proteins (Campbell and Reece, 2005). Lipid constitutes approximately 50% of 
most animal cell membranes in which phospholipids are the most abundant membrane 
lipids. A phospholipid molecule consists of a polar head group and two fatty acids tails 
in which one tail contains one or more cis-double bonds (unsaturated) which create a 
small kink in the tail, while the other tail does not (Alberts et al., 2002). A glycerol 
molecule is attached to one end of two fatty acids and to the other end of a phosphate 
group linked to an organic compound such as choline (Figure 2.1). The fatty acids tails 
are hydrophobic and not soluble in water whereas the hydrophilic polar head group is 
ionized and readily water soluble to enable interaction with the environment (Solomon 
et al., 2004). Due to its amphiphilic properties, phospholipids are spontaneously 
arranged in lipid bilayers in aqueous solution and aggregated into membranous 
structures (Alberts et al., 2002). These fundamental components make them uniquely 
suited to form membranes of living cells (Marinetti, 1990).  
 
Phospholipids are categorized into two major classes namely glycerophospholipids and 
sphingolipids based on their alcohol structure. Glycerophospholipids and sphingolipids 
contain glycerol and sphingosine respectively as the alcohol group (Newsholme and 






Figure 2.1 Structure of phospholipid and a phospholipid bilayer. a) A phospholipid 
consists of a hydrophobic tail made up of two fatty acids and a 
hydrophilic head consists of a glycerol bonded to a phosphate group, 
which in turn bonded to an organic group, choline. The fatty acid at the 
top contains one double bond that produces a kink in the chain. b) 
Phospholipids form lipid bilayers where the hydrophilic head interacts 
with water whereas the hydrophobic tails are arranged in bilayers. 







functions depending on their chemical structure. Glycerophospholipids mainly act as 
structural components of cell membranes while sphingolipids are often used as part of a 
signaling cascade (Lim and Kwan, 2018).  
 
2.1.1 Phosphatidylcholine 
Phosphatidylcholine (PC) is the major glycerophospholipid, accounting for 40-50% of 
total phospholipids in all eukaryotic membranes. This is followed by 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), 
sphingomyelin, cardiolipin and its phosphorylated derivatives which are also 
predominant in plasma membrane (Table 2.1) (Vance, 2015). PC plays a vital role in 
maintaining the cells and is found in all the subcellular components of the nervous 
system (Ansell, 1972). A study by Chakravarthy et al. (2009) discovered an isoform of 
PC, known as 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) that serves as 
endogenous ligand for Peroxisome Proliferator-Activated Receptor (PPARs) in 
hepatocytes. PPAR plays regulatory roles in gene expression and has been used as drug 
target to treat human disorders of lipid metabolism. PPARα-dependent gene expression 
is reduced with inactivation of fatty acid synthase (FAS) in the hypothalamus, which is 
required for the presence of POPC. However, injection of POPC into the hepatic veins 
of mice for several days induced PPARα-dependent gene expression and decreased 
hepatic steatosis. These data suggest that POPC is able to influence gene expression and 
acts as signaling molecule in mammals (Chakravarthy et al., 2009). 
 
PC also plays a distinct role in insulin transduction (Furse and De Kroon, 2015). 
Phosphatidylcholine transfer protein (PC-TP) is a phospholipid-binding protein that 
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catalyzes the intermembrane exchange of phosphatidylcholine in vitro (Wirtz, 1991; 
Kang et al., 2010). Elsoy and colleagues (2013) reported that PC-TP inhibits Insulin 
Receptor Substrate 2 (IRS2), which is an effector of insulin signaling that is impaired in 
diabetes, suggesting the functional role of PC-TP as a sensor of membrane 
phosphatidylcolines (Ersoy et al., 2013).  
 
2.2 CDP-choline pathway 
PC biosynthesis in all mammalian cells is synthesized mainly via the CDP-choline 
pathway, also known as Kennedy pathway (McMaster, 2018). This pathway consists of 
three steps: the first reaction of choline phosphorylation to form phosphocholine (PCho) 
is catalyzed by choline kinase (CK) using ATP and Mg
2+
 as cofactor. This is followed 
by the formation of CDP-choline from PCho which is catalyzed by cytidyltransferase 
(CCT), and final condensation of CDP-choline with a lipid anchor, diacylglycerol 
(DAG) to PC catalyzed by cholinephosphotransferase (CPT) (Figure 2.2) (Aoyama et 
al., 2004). During the biosynthesis of PC, the conversion of choline into PC accounts for 
approximately 95% of the total choline embedded in most animal tissues, whereas the 
remaining 5% consists of free choline, phosphocholine, glycerophosphocholine, CDP-
choline and acetylcholine (Li and Vance, 2008). 
 
2.3 Choline kinase 
The first step of PC biosynthesis involves choline kinase. Choline kinase (CK, 
ATP:choline phosphotransferase) was discovered in 1953 in Brewer’s yeast by 







Table 2.1 Lipid composition of a typical nucleated mammalian cell. Adapted from 
Vance (2015). 
 Percentage of total lipids
a 
Phosphatidylcholine 45 – 55 
Phosphatidylethanolamine 15 – 25 
Phosphatidylinositol  10 - 15 
Phosphatidylserine 5 – 10 
Phosphatidic acid 1 – 2 
Sphingomyelin 5 – 10 
Cardiolipin 2 – 5 
Phosphatidylglycerol <1 
Glycosphingolipids 2 – 5 
Cholesterol 10 - 20 
a 












present in various tissues in which the enzymatic activity has been observed to occur in 
liver, brain, intestine and kidney of several species (Wittenberg and Kornberg, 1953). 
CK is the first enzyme in the CDP-choline pathway for the de novo biosynthesis of PC 
(Farine et al., 2015) and changes in CK can influence the rate of PC synthesis (Gibellini 
and Smith, 2010). Until its purification in 1984, subsequent cloning and expression of 
cDNA of CK from yeasts, mammals and plants have been characterized which led to the 
description of the gene structure (Wu and Vance, 2010).  
 
In mammalian cells, CK exists in three isoforms namely CKα1 (50 kDa, 435 amino 
acids), CKα2 (52 kDa, 453 amino acids) and CKβ (45 kDa, 394 amino acids) which are 
encoded by two separate genes that are ckα and ckβ, located on chromosomes 11q13.2 
and 23q13.33, respectively (National Center for Biotechnology Information (NCBI). 
Available from: https://www.ncbi.nlm.nih.gov/). The CKα1 and CKα2 functional 
isoforms are the results of alternative splicing of CKα transcript which differ in an 
additional 54 bp extra internal nucleotide sequence, yielding 18 amino acids insertion 
starting at nucleotide 155 for CKα2. On the other hand, protein sequence of CKβ shares 
approximately 60% sequence identity with CKα1 and CKα2. CK isoform is active only 
in either homo or heterodimeric form but not in monomeric form in which α/α 
homodimer is the most active form, followed by α/β heterodimer and β/β homodimer 
which is the less active phenotype (Aoyama et al., 2004; Arlauckas et al., 2016).  
 
2.3.1 Expression and regulation of CK activity 
CKα and CKβ are both ubiquitously expressed in mammalian cells, yet the distribution 





Figure 2.2 The CDP-choline pathway. CK, choline kinase; CCT, CTP:phosphocholine 
cytidyltransferase; CPT,cholinephosphotransferase; PC, phosphatidylcholine; 
DAG, diacylglycerol; CMP, cytidine monophosphate; PCho, phosphocholine; 










and distribution of CK isoforms in mouse tissue using both Northern blot and Western 
blot analysis shows the expression of CKα isoform is the highest in the testis, whereas 
that of CKβ isoform is comparatively high in the heart and liver (Aoyama et al., 2002; 
Arlauckas et al., 2016). Further investigation was carried out to estimate each CK 
isoform activity in the mouse tissue by immunoprecipitation with each isoform-specific 
antiserum. They found out that the addition of anti-CKα and anti-CKβ antisera mixture 
in mouse tissue cytosols resulted in complete inhibition of CK activity (Aoyama et al., 
2002). This finding indicates that each CK isoform plays a distinct function in the 
expression of mammalian cells. 
 
In addition to its involvement in the biosynthesis of PC, CK also has other functions in 
regulating the cell signaling pathway. Downregulation of ckα expression with small 
interfering RNA (siRNA) silencing decreased the phosphatidylcholine, phosphatidic 
acid and signaling through the MAPK and P13/AKT pathway, which has been 
associated with cell proliferation (Yalcin et al., 2010). In another study, a group of 
researchers discovered that CKα forms a complex with EGFR in a c-Src dependent 
manner in which overexpression of EGFR and c-Src ultimately increases the total 
cellular activity and protein levels of CKα (Miyake and Parsons, 2012). EGFR and c-Src 
has been shown to have a synergistic effect in the tumorigenesis of breast as well as 
other cancers. Mutations of ckα introduced at Y197 and Y333 resulted in reduced 
complex formation, EGFR-dependent activation of CKα enzyme activity and EGF-




Several studies discovered the regulation of CK activity at the transcriptional level 
(Uchida, 1994; Aoyama et al., 2000; Glunde et al., 2008). Characterization of human 
putative promoter region of ckα gene (-2.3 kb region upstream of translation start site) 
shows that hypoxic environment regulates the expression of CKα and consequently 
increasing cellular PC and total choline levels (Glunde et al., 2008). The binding of 
hypoxia-inducible factor (HIF-α) on the HRE sites was shown to suppress ckα mRNA 
levels in a human prostate cancer model as shown through chromatin 
immunoprecipitation assay (Glunde et al., 2008). 
 
2.3.2 CK and carcinogenesis 
Cancer is characterized by uncontrolled cell growth due to uncontrolled proliferation and 
decreased apoptosis which is capable of invading adjacent tissues and organs. It is 
postulated that cancer is derived from the accumulation of mutated genes including 
tumor suppressor genes, oncogenes as well as invasion/metastasis related genes, where 
certain mutation may lead to development of malignant changes in their enzymatic 
activities (Han et al., 2019). Aberrant lipid metabolism has been observed in many types 
of cancer in which as tumor cells and tumor progresses, phospholipid biosynthesis 
become greater than in normal tissue (Szachowicz-Petelska et al., 2013; Sola-Leyva et 
al., 2019). Elevated activities of CK and its product, PC has been implicated in 
carcinogenesis as demonstrated by a large number of magnetic resonance spectroscopy 
(MRS) studies in cancer cells and solid tumors (Negendank, 1992; Nakagami et al., 
1999; Ronen and Leach, 2000). This elevation has been observed in most cancer types 




Overexpression of ckα gene has been reported in a number of human tumor-derived cell 
lines and in biopsy samples of colon, lung, ovarian and prostate carcinomas when 
compared with normal tissue (de Molina et al., 2007; Granata et al., 2014; Bagnoli et al., 
2016). This indicates that ckα is crucial in PC biosynthesis and is required to control the 
development of cancer cells (Glunde et al., 2011). In contrast, there was no evidence to 
implicate ckβ in carcinogenesis as no changes of ckβ expression was detected in breast, 
lung and ovarian cancer cell lines (Eliyahu et al., 2007; Gallego-Ortega et al., 2009).  
 
An increased activity of ckα was shown in human breast cancers where a significant 
increase of ckα activity was observed in approximately 38.5% tumor samples compared 
to the corresponding normal tissue (de Molina et al., 2002; Rizzo et al., 2021). 
Ovverexpression and increased activity of ckα correlated with histological tumor grade 
suggesting that ckα dysregulation might be associated with prognosis and malignancy of 
the disease. However, no significant correlation was observed with age, tumor size or 
progesterone receptor status in these studied breast tumors. These findings suggest that 
ckα activity is directly associated with increased breast cancer proliferation making it a 
potential marker for breast prognosis (de Molina et al., 2002). 
 
The involvement of ckα in carcinogenesis suggests that ckα inhibition could be an 
effective cancer therapy. Early discovery of CK inhibitors includes the study of choline 
phosphorylation  in the presence of the thiol group inhibitors that leads to CK inhibition 
by N-ethylmaleimide (Arlauckas et al., 2016). A preliminary study targeting the 
inhibition of choline kinase using purinyl-6-histamine (PH), which is selectively 
cytotoxic against tumor cells demonstrated the inhibition of choline phosphorylation, 
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reflecting its anti-tumor activity (Mayer and Werner, 1974). Hemicholinium-3 (HC-3), a 
well-known CK inhibitor is shown to reduce PC levels and reduce the growth factor-
induced DNA synthesis in vitro (Arlauckas et al., 2016). Glunde et al. (2005) reported a 
molecular approach by RNA interference (RNAi) to inhibit the expression of specific 
targeted genes in mammalian cells. RNAi knockdown of CK reduced proliferation and 
promoted differentiation of breast cancer cells as detected by MRS (Glunde et al., 2005). 
Specific inhibition of ckα selectively induces apoptosis in several cancer cell lines while 
the normal cell is not affected (Bañez-Coronel et al., 2008). 
 
2.4 Promoter and transcriptional regulation of gene expression 
The expression of a gene is regulated at different stages from transcription initiation to 
post-translational modification of protein. However, the key factor for proper 
functioning of regulatory elements occur at the level of transcription initiation, 
particularly gene promoter which is crucial for coordinated transcription within a cell 
(De Vooght et al., 2009). Till date, the structure of regulatory DNA sequences remains 
poorly understood. With a variety of DNA regulatory elements present within promoter 
region, the identification and characterization of these elements are crucial for the 
understanding of the human gene regulation.  
 
Promoters are stretches of genomic sequence typically located upstream of a gene. Core 
promoter is a promoter region typically 60-120 bp, surrounding the transcription start 
site (TSS) that recruits a complex of general transcription factors for the initiation of 
transcription (Haberle et al., 2014). This minimal promoter region is sufficient to direct 
the accurate initiation of transcription. Sequence motifs commonly found within the core 
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promoter region includes TFIIB recognition element (BRE), initiator (Inr), TATA box 
and downstream core promoter element (DPE) (Butler and Kadonaga, 2002). Each of 
these motifs specifically involves in the initiation of transcription process, though these 
elements are not necessarily present in all core promoters. The core promoter provides a 
docking site for RNA Polymerase II transcriptional machinery in a tightly regulated 
manner for a proper level of gene expression (Kumar and Bansal, 2018). RNA 
Polymerase II requires specific core promoter element to initiate transcription through 
the assembly of transcription preinitiation complex (PIC). This process requires general 
transcription factors (GTFs) that recognize and bind core promoter motifs and 
subsequently direct RNA Polymerase II to the TSS and starts the transcription of a gene. 
The common GTFs bind to the core promoter in the following order: TFIID, TFIIB, 
RNA Polymerase II-TFIIF complex, TFIIE, followed by TFIIH (Héberlé and Bardet, 
2019). 
 
In addition to basal transcriptional regulation of core promoter, transcriptional activity is 
greatly stimulated by a concerted action of other elements including proximal promoter 
elements such as enhancers, silencers and insulators (Figure 2.3) (Butler and Kadonaga, 
2002; Hernandez-Garcia and Finer, 2014). Proximal promoter elements such as CAAT 
box, cis-regulatory module (CRM) and GC box which are located immediate upstream 
of core promoter, contain recognition sites for specific consensus elements that involved 
in transcriptional regulation (Kumar and Bansal, 2018). Proximal promoter elements 
which are present in the distal promoter region are mainly act as connecting element for 








Figure 2.3 Schematic structure of a gene promoter region. The promoter composed 
of core promoter and proximal promoter elements typically span less than 
1 kb pairs. Distal promoter elements located upstream of the promoter 
includes enhancers, silencers and insulators. These distal elements may 
contact the core promoter or proximal promoter by looping out the 









Cis-regulatory elements are regions of non-coding DNA which regulate the transcription 
of neighboring genes, whereas trans-regulatory elements regulate the expression of 
distant genes. Transcription initiation is a strictly controlled process that involves both 
cis-acting and trans-acting factors (Das and Singal, 2004). The presence of both positive 
and negative regulatory elements within the promoter provides regulatory control of a 
unique gene expression pattern (Maston et al., 2006).  
 
The upstream trans-acting DNA binding transcription factors such as activators and 
coactivators, interact with the regulatory element within core promoter, proximal 
promoter elements and distal promoter to enhance the efficiency of transcription 
initiation. On the other hand, transcription can be inhibited by trans-acting repressors 
which directly or indirectly bind to DNA binding motif and negatively regulate gene 
transcription. A study using full-length cDNA sequence for the identification of TSS in 
the transcriptional human promoters revealed that putative negative regulatory elements 
were located at -1000 to -500 bp upstream of the TSS for 55% genes tested (Cooper et 
al., 2006).  
 
Activators or repressors regulate gene transcription mostly through coregulators, even 
though they can bind directly with PIC complex associated with core promoter (Fuda et 
al., 2009). These processes are important in a mediation of precise controlled patterns of 
gene expression (Maston et al., 2006).  A study of the 5’ flanking sequence of mouse 
ckα gene by the promoter-reporter assay reveal the presence of two putative promoter 
regions which are proximal and distal promoter. Various Sp-1 consensus sequences are 
identified within the proximal region indicating the criteria of housekeeping gene for ckα 
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gene. Meanwhile, distal promoter consists of responsive elements such as XRE and AP-
1 boxes which demonstrated a high expression of ckα. AP-1 binding element responds to 
carbon tetrachloride (CCl4) which resulted in increased expression level of ckα mRNA 
and CK activity in murine liver. Deletion of 9 base pair (bp) sequence corresponding to 
AP-1 binding element resulted in the loss of promoter activity whereas the duplication 
insertion of this 9 bp element caused an increase in promoter activity. These results 
indicated that ckα gene expression is positively regulated by AP-1 or together with other 
transcription factors that could be involved in the promoter activity (Aoyama et al., 
2004). In contrast, no distal promoter sequence has been found in 5’ flanking region of 
ckβ gene indicating the absence of any responsive elements in its regulatory region 
(Figure 2.4) (Aoyama et al., 2004).  
 
2.5 Epigenetics 
Epigenetics is a study of heritable changes in gene expression that occur without any 
changes in DNA sequence (Bird, 2007). The term epigenetics was first coined by 
Conrad Waddington in 1942 to describe the influence of internal and external 
interactions between genes and the microenvironment towards the development of 
phenotype (Goldberg et al., 2007). Epigenetic modifications are required for normal 
development and are involved in a variety of cellular differentiation, morphogenesis and 
variability of an organism. This process influences gene activity at the transcriptional 
and post-trasncriptional level as well as at the translational and post-translational protein 
level (Halušková, 2010). Dysregulated epigenetics processes have been found to be 
involved in various diseases, particularly cancers, immune disorders and mental 







Figure 2.4 Schematic structure of murine ckα and ckβ promoters. The predicted 
contribution of AP-1 and XRE sites of ckα gene in CCl4 and PAH-












Back in 1983, cancer was the first human diseases to be linked to epigenetics (Feinberg 
and Vogelstein, 1983). Cytosine methylation of hMLH1 promoter was reported in four 
colorectal tumor cell lines but absent in adjacent normal tissue that expressed hMLH1 
which results in silencing of the gene encoding MLH1 (Kane et al., 1997). The most 
characterized epigenetic modifications include DNA methylation, chromatin 
remodeling, modifications of histones, non-coding RNA mechanisms and positioning of 
nucleosome along the DNA (Kulis and Esteller, 2010). These epigenetic signals work 
synergistically to ensure proper transcriptional activity and repression by chromatin-
modifying activity.  
 
2.6 DNA methylation  
DNA methylation is the most common epigenetic modifications in vertebrates and is 
originally proposed as a silencing epigenetic mark in 1970s (Holliday and Pugh, 1975; 
Riggs, 1975). In mammals, DNA methylation occurs exclusively at cytosine residues 
that precede a guanine nucleotide or known as CpG sites (Feltus et al., 2003). The ‘p’ 
indicates cytosine (C) and guanine (G) are connected by a phosphodiester bond. 
Approximately 5 x 10
7
 of total cytosines are methylated per diploid nucleus. Although 
all methylated cytosines are present within CpG dinucleotides, only 70-80% of these 
potentially methylated sites are actually in a methylated form (Antequera and Bird, 
1993). 
 
DNA methylation involves the covalent addition of a methyl group (CH3) at the 5-
carbon of the cytosine ring which results in the conversion of cytosine to 5-
methylcytosine (5-mC). The methyl groups protrude into the major groove of DNA and 
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provides molecular interactions within major grooves of DNA double helix (Fatemi and 
Wade, 2006). The modified cytosine was first discovered during the separation of DNA 
nucleosides by paper chromatography (Hotchkiss, 1948). However, it was not until two 
decades later that DNA methylation was demonstrated to be involved in cellular 
differentiation and regulation of gene expression at the transcriptional level (Holliday 
and Pugh, 1975; Compere and Palmiter, 1981). 
 
DNA methylation patterns are established during early embryonic development and 
stably maintained throughout an individual’s life. Several hours after conception, sperm 
DNA is exposed to methylation in the single-celled embryo. The cells begin to 
differentiate into various tissue types as the embryo started to develop and divide, 
gradually establishing the methylation pattern. However, an active demethylation occurs 
mostly in paternal genomes during the early steps of embryo development immediately 
after fertilization and in pre implantation embryos (Geiman and Robertson, 2002). This 
process is followed by the establishment of global de novo methylation patterns 
following implantation (Almouzni and Cedar, 2016) that will be maintained 
predominantly in somatic tissues (Chen and Riggs, 2011). 
 
2.6.1 DNA methyltransferases family 
DNA methylation is regulated by a group of DNA methyltransferase (DNMT) protein 
family; DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L (Espada and Esteller, 
2007; Cheng and Blumenthal, 2008). These enzymes work synergistically for the 
establishment, recognition and removal of DNA methylation throughout the genome 
(Moore et al., 2013). DNMT3A and DNMT3B are de novo methyltransferases that are 
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highly expressed in developing embryo, responsible for the establishment of DNA 
methylation profile during embryonic stage (Heerboth et al., 2014). On the other hand, 
DNMT1 is a maintenance methyltransferase that is found abundantly in somatic cells, 
and has 30 to 40~folds preference to methylate hemimethylated DNA and maintaining 
methylation pattern from the parental to the daughter strand during DNA replication 
(Jeltsch, 2006; Espada and Esteller, 2007). A strong preferential binding to 
hemimethylated CG sites is shown by a multidomain protein UHRF1 as it interacts and 
colocalizes with DNMT1 for stable association of DNMT1 to chromatin. This particular 
protein contains a methyl DNA binding domain, SRA (SET and RING associated) 
domain which involved in the recruitment of DNMT1 to hemimethylated DNA in order 
to facilitate efficient maintenance of DNA methylation (Bostick et al., 2007). In some 
cases, de novo methyltransferases, DNMT3A and DNMT3B act as maintenance of DNA 
methylation patterns by methylating the hemimethylated CG dinucleotides (Chen and 
Riggs, 2011).  
 
Unlike the aforementioned DNMT family members, another member of DNMT3 family, 
DNMT3L lacks conserved motif and is catalytically inactive. It has been postulated that 
DNMT3L functions as regulatory factors in germ cells by recruiting DNMT3A isoforms 
to nucleosome that contain unmethylated H3K4 to trigger de novo DNA methylation 
(Chen and Riggs, 2011). Owing to its role as the only DNA methyltransferase family 
that is expressed in germ cells, DNMT3L is crucial for the establishment of methylation 
patterns in both male and female germ cells (Bourc'his et al., 2001). 
 
